RT Journal Article
T1 Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics.
A1 Delgado-Jiménez, Juan F
A1 Segovia-Cubero, Javier
A1 Almenar-Bonet, Luis
A1 de Juan-Bagudá, Javier
A1 Lara-Padrón, Antonio
A1 García-Pinilla, José Manuel
A1 Bonilla-Palomas, Juan Luis
A1 López-Fernández, Silvia
A1 Mirabet-Pérez, Sonia
A1 Gómez-Otero, Inés
A1 Castro-Fernández, Antonio
A1 Díaz-Molina, Beatriz
A1 Goirigolzarri-Artaza, Josebe
A1 Rincón-Díaz, Luis Miguel
A1 Pascual-Figal, Domingo Andrés
A1 Anguita-Sánchez, Manuel
A1 Muñiz, Javier
A1 Crespo-Leiro, María G
K1 heart failure
K1 hyperkalaemia
K1 medical treatment
AB Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial fibrillation, 43% were diabetic, 42% had a glomerular filtration rate
SN 2077-0383
YR 2022
FD 2022-02-22
LK http://hdl.handle.net/10668/21244
UL http://hdl.handle.net/10668/21244
LA en
DS RISalud
RD Apr 19, 2025